Evaluation of the orofacial antinociceptive profile of the ethyl acetate fraction and its major constituent, rosmarinic acid, from the leaves of Hyptis pectinata on rodents  by Falcão, Rosângela E.A. et al.
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a  b  s  t  r  a  c  t
Hyptis  pectinata  (L.) Poit.,  Lamiaceae,  popularly  known  as “sambacaitá,”  is  an  aromatic  shrub  largely
grown  in  the  Brazilian  northeastern.  We  investigated  the  antinociceptive  effects  of  the  ethyl  acetate
fraction  obtained  from  the  leaves  of  H.  pectinata  and of  its  main  constituent  rosmarinic  acid,  on  for-
malin  (2%)-,  glutamate  (25  M)-  and  capsaicin  (2.5  g)-induced  orofacial  nociception  in rodents.  Male
mice  were  pretreated  with  ethyl  acetate  fraction  (100,  200  or 400  mg/kg,  p.o.),  rosmarinic  acid  (10  or
20 mg/kg,  p.o.),  morphine  (5 mg/kg,  i.p.),  or  vehicle  (distilled  water  +  0.2% Tween  80). Ethyl  acetate  frac-osmarinic acid
rofacial pain
ociception
tion  reduced  the  nociceptive  face-rubbing  behavior  during  the  two  phase  of  the  formalin  test,  whereas
pretreatment  with  rosmarinic  acid  decreased  the  pain  behavior  in  the  second  phase.  Ethyl  acetate  frac-
tion produced  signiﬁcant  antinociceptive  effects  in  the  capsaicin  and  glutamate  tests.  This  study  showed
that  oral administration  of  ethyl  acetate  fraction  produced  potent  antinociceptive  effects  compared  to
treatment  with  rosmarinic  acid.
© 2015 Sociedade  Brasileira  de  Farmacognosia.  Published  by Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
Pain in the oral and craniofacial system represents a major med-
cal and social problem (Hargreaves, 2011). Indeed, a report from
he U.S. Surgeon General on orofacial health concludes that, “. . .oral
ealth means much more than healthy teeth. It means being
ree of chronic oral-facial pain conditions.  . .”  (National Institutes
f Health, 2000). Moreover, orofacial pain is derived from many
nique target tissues, such as the meninges, cornea, tooth pulp,
ral/nasal mucosa, and temporomandibular joint, and thus has sev-
ral unique physiologic characteristics compared with the spinal
ociceptive system (Bereiter et al., 2008; Hargreaves, 2011). Thus,
he management or treatment of orofacial pain conditions rep-
esents a signiﬁcant health care problem and a challenge for the
harmaceutical industry.
∗ Corresponding author.
E-mail: adrianagibara@pq.cnpq.br (A.G. Guimarães).
http://dx.doi.org/10.1016/j.bjp.2015.07.029
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier EditoraIn the last couple of decades, important progress has been made
regarding the development of natural therapies. However, there
is an urgent need to discover effective and safe analgesic agents
(Calixto et al., 2000) and natural products have been shown to be
strong candidates for development of new drugs for pain control
(Quintans et al., 2014; Siqueira-Lima et al., 2014). Besides, a current
approach is to develop new biological compounds from natural
products that manage orofacial pain with enhanced efﬁcacy and
minimal side effects; these compounds are derived from medici-
nal plants or their secondary metabolites (Bonjardim et al., 2012;
Guimarães et al., 2013; Quintans-Júnior et al., 2010; Venâncio et al.,
2011).
Hyptis pectinata (L.) Poit., Laminaceae, is a medicinal plant
known as “sambacaitá” or “canudinho” in northeastern Brazil that
is widely used to treat gastrointestinal disorders, skin infections,
nasal congestion, fever, cramps, inﬂammation and pain (Bispo et al.,
2001; Raymundo et al., 2011). Some studies have demonstrated
that H. pectinata possesses antinociceptive and anti-inﬂammatory
activities (Bispo et al., 2001; Lisboa et al., 2006; Raymundo et al.,
 Ltda. All rights reserved.
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0.1 ml/10 g, with the exception of the nociception inducing agents,
such as formalin, glutamate and capsaicin, which were injected
subcutaneously (s.c.) into the right upper lip.
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Fig. 2. Effects of EtOAc fraction (Hyptis pectinata), rosmarinic acid (RA) or morphine0.0 5.0 10.0
Fig. 1. Chromatogram from HPLC-DAD analysis and the compou
011). Nascimento et al. (2008) described how H. pectinata leaves
re used as treatment for several oral diseases, such as dental caries
nd orofacial pain. This pharmacological proﬁle was  corroborated
y Paixão et al. (2013, 2015), who demonstrated an important neu-
ogenic and inﬂammatory orofacial antinociceptive proﬁle of the
rude aqueous extract obtained from H. pectinata leaves and its
ossible application against other orofacial diseases such as peri-
dontitis.
Besides, Arrigoni-Blank et al. (2005) demonstrated anti-
dematogenic effect of the aqueous extract of H. pectinata. Hasanein
nd Mohammad Zaheri (2014) showed that rosmarinic acid (1), an
ster of caffeic acid found in Hyptis species, reduces nociception
n painful diabetic neuropathy model. Nevertheless, little is known
ow H. pectinata extract modulates orofacial pain transmission.
The present study proposed to verify the antinociceptive prop-
rties of the ethyl acetate fraction (EtOAc) of H. pectinata leaves and,
n particular, rosmarinic acid (1) (RA), which was the major com-
ound isolated from this fraction. The antinociceptive properties
f EtOAc fraction were tested on mice following orofacial nocicep-
ion induced by formalin, capsaicin and glutamate, three algogens
gents that promote pain through different mechanisms and also
y activation of different neuronal populations.
aterials and methods
lant material
Plant material was obtained and extracted according to proto-
ols described in Falcão et al. (2013). Voucher specimen (88157) is
eposited at the Instituto Agronômico de Pernambuco, Recife, PE.
rieﬂy, the leaves were dried, crushed and successively extracted
ith EtOH to obtain 7 g dry extract. This extract was dissolved
n MeOH:H2O (1:1) and successively fractionated with hexane
nd EtOAc. A portion of the EtOAc fraction (3.5 g) was subjected
o chromatography on a Sephadex LH-20 column, and the com-
ounds were puriﬁed using a semi-preparative HPLC column.
his fractionation resulted in the isolation of sambacaitaric acid
2), 3-O-methyl-sambacaitaric acid (3), rosmarinic acid (1), 3-O-
ethyl-rosmarinic acid (4), ethyl caffeoate (5), nepetoidin A (6),
epetoidin B (7), cirsiliol (8), cirsimaritin (9), 7-O-methylluteolin
10) and genkwanin (11) (Falcão et al., 2013). Rosmarinic acid was
he major compound isolated from the EtOAc fraction, as shown in
he chromatogram (Fig. 1) obtained by HPLC-DAD analysis.
nimalsMale Swiss mice (28–34 g), 2–3 months of age, were used
hroughout this study. The animals were randomly housed in
ppropriate cages at 22 ± 2 ◦C on a 12 h light/dark cycle (lights on.0 20.0 25.0 min
olated from the EtOAc fraction of the leaves of Hyptis pectinata.
between 6 am and 6 pm)  with free access to food and water. All
experiments were carried out between 9 am and 2 pm in a quiet
room. All nociception tests were carried out by the same visual
observer, and behavioral tests were performed under blind condi-
tions. Experimental protocols were approved by the Animal Care
and Use Committee at the Federal University of Sergipe (CEPA/UFS
# 10/11).
Drug and treatments
Morphine hydrochloride (União Química, Brazil), 37% formalde-
hyde (Vetec, Brazil), diazepam (Roche, Brazil), Tween 80
(polyoxyethylene-sorbitan monooleate), glutamate, capsaicin and
rosmarinic acid (RA) were purchased from Sigma (USA). During the
nociception tests, the extract or agent was  administrated by oral
gavage (p.o., per os)  or intraperitoneally (i.p.) at a dose volume of(MOR) on formalin-induced orofacial nociception in mice. Vehicle (control), EtOAc
(100, 200 or 400 mg/kg, p.o.), RA (10 or 20 mg/kg, p.o.) or MOR  (5 mg/kg, i.p.)  were
administered 1 h before formalin injection. (A) First phase (0–5 min) and (B) sec-
ond phase (15–40 min). Each column represents the mean ± S.E.M. (n = 8 per group).
*p  < 0.05 or **p < 0.001 vs. the control (ANOVA followed by Tukey’s test).
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ociception studies
ormalin test
Orofacial nociception was induced in mice by s.c. injection of
0 l 2% formalin into the right upper lip (perinasal area), using
 27-gauge needle (Luccarini et al., 2006; Pelissier et al., 2002)
ccording to previously reported methods with changes (Quintans-
únior et al., 2010). This volume and concentration of formalin was
elected during our pilot studies because it showed an intense
ociception-related biphasic behavioral response (face-rubbing)
t periods of 0–5 min  (ﬁrst phase) and 15–40 min  (second phase)
Quintans-Júnior et al., 2010). Nociceptive behavior was  quantiﬁed
uring these periods by measuring the time (s) that the mice spent
ubbing their face at the injection area with its fore or hind paws
Luccarini et al., 2006). To assess the effects of the test drugs, groups
f mice (n = 8 per group) were pretreated systemically with a vehi-
le control (distilled water + 0.2% Tween 80), EtOAc (100, 200 or
00 mg/kg, p.o.), or RA (10 or 20 mg/kg, p.o.) 1 h before the injec-
ion of formalin. Morphine (MOR, 5 mg/kg, i.p.)  was administered
 h before of nociceptive agent, as a positive control.
apsaicin and glutamate tests
The orofacial nociception induced by capsaicin or glutamate in
odents was performed as described previously by Quintans-Júnior
t al. (2010). Mice (n = 8 per group) were injected with capsaicin
20 l, 2.5 mg)  or glutamate (40 l, 25 M prepared in phosphate
uffered saline) subcutaneously into the right upper lip (perinasal
rea), using a 27-gauge needle. Capsaicin was dissolved in ethanol,
imethyl sulfoxide and distilled water (1:1:8). An additional group
eceived a similar volume of the capsaicin vehicle. Nociception
uantiﬁcation was performed by measuring the time(s) that the
nimals spent rubbing the orofacial region with greater intensity
or a period of 42 and 30 min  after the injection of capsaicin and glu-
amate, respectively. The EtOAc fraction (100, 200 or 400 mg/kg) or
ehicle (distilled water + 0.2% Tween 80) was given by oral gavage
o animals 1 h before the injection of capsaicin or glutamate, similar
o the formalin test. MOR  was used as a positive control and was
dministered (5 mg/kg, i.p.) 1 h before the nociception-inducing
gent.
valuation of motor activity
In order to evaluate a possible non-speciﬁc muscle-relaxant or
edative effect of the extract, mice were submitted to the Rota-rod
pparatus, as described by Quintans-Júnior et al. (2010). Initially,
4 h before the test, the mice that were able to remain on the Rota-
od apparatus (AVS®, Brazil) longer than 180 s, at a speed of 9 rpm,
ere selected. Mice were treated with the EtOAc fraction (100, 200or 400 mg/kg, p.o.), vehicle or diazepam (3 mg/kg, i.p.) 1, 2 and 4 h
before being placed on the Rota-rod; each animal was tested on the
Rota-rod apparatus, and the time (s) that the animal remained on
the bar for up to 180 s was  recorded.
Statistical analysis
Data obtained from the animal experiments were expressed as
the mean ± the standard error of the mean (mean ± S.E.M.). Signif-
icant differences between the treated and the control groups were
evaluated using the ANOVA and Tukey tests. Differences were con-
sidered to be statistically signiﬁcant when p < 0.05. All statistical
analyses were performed using GraphPad Prism 5 (Graph Pad Prism
Software Inc., San Diego, CA, USA).
Results
The chemical analysis of the EtOAc fraction from H. pecti-
nata leaves showed the presence of eleven compounds and the
chromatogram (HPLC-DAD) is shown in Fig. 1. As seen in the
chromatogram, rosmarinic acid (1) was the main component of
this fraction. Four of the eleven isolated compounds are derived
from rosmarinic acid, and compounds 2 (sambacaitaric acid) and
3 (3-O-methyl sambacaitaric acid) were identiﬁed as new natural
compounds.
Acute treatment of mice with the EtOAc fraction (100, 200
or 400 mg/kg, p.o.) produced a signiﬁcant reduction (p < 0.05 or
p < 0.001) in the face-rubbing behavior (Fig. 2A and B) in both
phases of formalin-induced nociception. Additionally, treatment
with rosmarinic acid (10 or 20 mg/kg, p.o.) alone was effective in sig-
niﬁcantly reducing of the nociceptive behaviors during the second
phase, p < 0.05 or p < 0.001 respectively.
As shown in Fig. 3A, pretreatment with the EtOAc fraction (100,
200 or 400 mg/kg, p.o.) signiﬁcantly reduced (p < 0.001) the face-
rubbing behavior induced by capsaicin treatment. As expected, the
group that received the vehicle treatment (ethanol, dimethyl sul-
foxide and distilled water 1:1:8) did not present any nociceptive
behavior (data not shown). Besides, acute treatment with the EtOAc
fraction produced a signiﬁcant reduction (p < 0.05 or p < 0.001) of
glutamate-induced nociception when compared with the control
group (Fig. 3B).
In the rota-rod test, EtOAc-treated mice did not show any sig-
niﬁcant motor performance alterations with the doses of 100, 200
or 400 mg/kg (Fig. 4). As expected, the CNS depressant diazepam
(3 mg/kg, standard drug), reduced the time of animals on the rota-
rod after 60, 120 and 240 min.
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Fig. 3. Effects of EtOAc (Hyptis pectinata) on (A) capsaicin- or (B) glutamate-induced
orofacial nociception in mice. Vehicle (control), EtOAc (100, 200 or 400 mg/kg, p.o.),
or  MOR  (5 mg/kg, i.p.) was administered 1 h before capsaicin or glutamate injection.
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s.  the control (ANOVA followed by Tukey’s test).
iscussion
In folk medicine used in northeastern Brazil, the H. pectinata
lant (“sambacaita”) is used in the treatment of several orofacial
athological disorders, including orofacial pain. However, there
re no pharmacological studies that report this effect. For the ﬁrst
ime, we demonstrate that oral administration of the EtOAc fraction
rom H. pectinata leaves exerts protective effects against formalin-
 capsaicin-, and glutamate-induced orofacial pain in mice; this
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effect may  be related to the presence of rosmarinic acid in this
fraction.
In this study, the eleven compounds of the EtOAc fraction from
H. pectinata leaves were isolated and identiﬁed according to the
protocols described by Falcão et al. (2013). Rosmarinic acid (RA), a
polyphenol commonly found in other species of this genus as Hyptis
atrorubens, was  identiﬁed as the main component of this fraction.
During the formalin test, the presence of two distinct phases
is at least partially due to the mechanisms of nociception. The ﬁrst
phase is associated with the direct stimulation of the C-nociceptors
by mechanisms dependent on TRPA1, whereas the second phase
reﬂects the integration between the peripheral (nociceptors) and
central (spinal/brainstem) signaling pathways (Capuano et al.,
2009; Dallel et al., 1995; McNamara et al., 2007). All tested doses of
EtOAc produced antinociception in both the ﬁrst and second phase
of the formalin test compared to the vehicle control. Synergistic
effect of compounds in the extract, as polyphenols and ﬂavonoids,
certainly contributed to the reduction of formalin-induced noci-
ception during the ﬁrst phase, since ﬂavonoids and phenols are
among the main natural products studied pain, as demonstrated
by Quintans et al. (2014).
Interestingly, Bispo et al. (2001) demonstrated that pretreating
mice with the aqueous extract of H. pectinata at the doses of 200
and 400 mg/kg had no signiﬁcant effect during the ﬁrst phase of the
formalin test, when the painful agent was  applied in the paw. How-
ever, Paixão et al. (2013) showed a marked antinociceptive effect of
the aqueous extract of H. pectinata in both phases of the orofacial
formalin test and attributed this proﬁle to a possible antioxidant
effect of the extract. The discrepancies in the results of Bispo et al.
(2001) and Paixão et al. (2013) may  be due to the greater sensitivity
of the orofacial region, the involvement of the trigeminal pathway
(Sessle, 2011), or due the chemical variation of plant secondary
metabolites generated by environmental and genetic (Moore et al.,
2014).
RA reduced only late phase of formalin test. A previous study
showed that the administration of RA at higher doses reduces
both phases of formalin-induced nociception, with the involvement
of opioid mechanisms (Boonyarikpunchai et al., 2014; Hasanein
and Mohammad Zaheri, 2014). Furthermore, this compound and
some analogs could be useful in the prevention and treatment of
inﬂammatory diseases, and inhibit inﬂammatory responses, suchet al., 2011).
Capsaicin, an active ingredient in hot chili peppers, directly
stimulates transient receptor potential cation channel subfamily
*
4h
Vehicle 200 400100 DZP
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00 400 DZP
c (mg/kg)
*
ol), EtOAc (100, 200 or 400 mg/kg, p.o.), or diazepam (DZP, 3 mg/kg, i.p.). The motor
al remained on the bar for up to 180 s was recorded. Signiﬁcant differences vs. the
oup). *p < 0.001.
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 member 1 (TRPV1), which are involved in the transmission and
odulation of nociceptive activity, through selective actions on
nmyelinated C-ﬁbers and thinly myelinated A primary sensory
eurones (Dray, 1992). Antagonists of TRPV1 receptors have been
eported to exhibit a pain-relieving activity (Trevisani, 2013) and
ere effective in reducing nociception from inﬂammatory as well
s neuropathic pain models in rats (Khairatkar-Joshi and Szallasi,
009). Based on our ﬁnding, the oral administration of EtOAc
roduced a neurogenic inhibition against capsaicin-induced noci-
eption indicating its ability to inhibit nociceptive transmission
nitiated by TRPV1 activation.
When glutamate is injected into the right upper lip (peri-
asal area) elicits a noxious stimulus characterized by a behavioral
esponse of rubbing the orofacial region (Quintans-Júnior et al.,
010; Siqueira et al., 2010). Noxious stimulation of primary afferent
bers results in the release of glutamate from the peripheral and
entral terminals of the trigeminal and spinal afferent ﬁbers (Keast
nd Stephensen, 2000; Lam et al., 2005). Our results demonstrated
hat EtOAc fraction reduced orofacial pain induced by glutamate.
hus, suggest that the suppression of glutamate-induced nocicep-
ion by EtOAc treatment can be associated to its interaction with
he glutamatergic system. These results are similar to those found
y Guginski et al. (2009), who demonstrated that rosmarinic acid
locks the pain induced by glutamate on the mouse paw.
In summary, we demonstrated the EtOAc effect on orofacial pain
nduced by three algogens agents, which promote nociception by
ifferent mechanisms as TRPA1, TRPV1 and glutamatergic recep-
ors (Caterina et al., 1997; McNamara et al., 2007; Willcockson and
altschanoff, 2008) with the possible participation of peptidergic
nd non-peptidergic primary afferent neurons (Kobayashi et al.,
005; Willcockson and Valtschanoff, 2008). Additionally, previous
tudy has shown the CNS action of the aqueous extract from H.
ectinata leaves on rodent central nervous system (Bueno et al.,
006), with possible involvement of opioid system (Bispo et al.,
001). Thus, it is suggested that EtOAc has central antinociceptive
ctions and may  be acting on perception of nociceptive stimuli,
ignal transduction or its conduction to the central nervous system
CNS).
In this sense drugs that act on the CNS, as diazepam or mor-
hine, can impair motor coordination and generate confusion in
nalysis of results of nociceptive behavioral tests, such as those
sed here (Quintans-Júnior et al., 2010). Therefore, we evaluated
hether pretreatment with EtOAc can impair the motor coordina-
ion of mice using a Rota-rod apparatus. However, all tested doses of
tOAc were ineffective in producing changes in motor coordination.
Taken altogether, our data led to the hypothesis that EtOAc had
 protective role in orofacial nociception in mice. These effects may
e related to the presence of rosmarinic acid and other compounds.
hese ﬁndings also support the hypothesis that H. pectinata has
otential therapeutic use for painful facial and, perhaps, dental dis-
rders. Nevertheless, further studies are needed to determine the
recise mechanism of action.
Taken altogether, our data led to the hypothesis that EtOAc had
 protective role in orofacial nociception in mice. These effects may
e related to the presence of rosmarinic acid and other compounds.
hese ﬁndings also support the hypothesis that H. pectinata has
otential therapeutic use for painful facial and, perhaps, dental dis-
rders. Nevertheless, further studies are needed to determine the
recise mechanism of action.
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